Clinical drug investigationHumansGlutathione TransferaseAdultMaleFemale
Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype.
Jaydeep Mehta, Chuck Thompson, Ellen Scheers, Laurent Leclercq, Seong Bok Jang, Dong Kyun Kim, Nahor Haddish-Berhane, Peter Hellemans, Juhui James Jiao, Pamela L Clemens
Published: 202510.1007/s40261-025-01494-z
Abstract
BACKGROUND AND OBJECTIVE: Lazertinib, a potent and irreversible third-generation oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown promising efficacy and favorable tolerability in EGFR-mutated non-small cell lung…
Preview only. Read the full abstract at the source